Browsing by Author "Sorio, R."
Now showing items 1-4 of 4
-
Article
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: A study of the EORTC early clinical studies group (ECSG)
Pavlidis, Nicholas; Aamdal, S.; Awada, Ahmad; Calvert, H.; Fumoleau, P.; Sorio, R.; Punt, C.; Verweij, J.; Oosterom, A. T. Van; Morant, R.; Wanders, J.; Hanauske, A. R. (2000)Purpose: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. Patients and methods: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ...
-
Article
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC early clinical studies group
Dirix, L. Y.; Tonnesen, F.; Cassidy, J.; Epelbaum, R.; Huinink, W. W. Ten Bokkel; Pavlidis, Nicholas; Sorio, R.; Gamucci, T.; Wolff, I.; Velde, A. Te; Lan, J.; Verweij, J. (1996)In a phase II trial, the activity of EO9, a new bioreductive alkylating agent, was assessed. EO9 was used as second-line chemotherapy in breast cancer patients and as first-line chemotherapy for patients with gastric, ...
-
Article
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG
Joerger, M.; Huitema, A. D. R.; Richel, D. J.; Dittrich, C.; Pavlidis, Nicholas; Briassoulis, E. Ch; Vermorken, J. B.; Strocchi, E.; Martoni, A.; Sorio, R.; Sleeboom, H. P.; Izquierdo, M. A.; Jodrell, D. I.; Féty, R.; Bruijn, E. De; Hempel, G.; Karlsson, M.; Tranchand, B.; Schrijvers, A. H. G. J.; Twelves, C.; Beijnen, J. H.; Schellens, J. H. M. (2007)Aims: To investigate the population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients. Patients and methods: Sixty-five female patients with early or advanced breast cancer ...
-
Article
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group
Joerger, M.; Huitema, A. D. R.; Richel, D. J.; Dittrich, C.; Pavlidis, Nicholas; Briassoulis, E. Ch; Vermorken, J. B.; Strocchi, E.; Martoni, A.; Sorio, R.; Sleeboom, H. P.; Izquierdo, M. A.; Jodrell, D. I.; Calvert, H.; Boddy, A. V.; Hollema, H.; Féty, R.; Vijgh, W. J. F. Van Der; Hempel, G.; Chatelut, E.; Karlsson, M.; Wilkins, J.; Tranchand, B.; Schrijvers, A. H. G. J.; Twelves, C.; Beijnen, J. H.; Schellens, J. H. M. (2007)Purpose: Paclitaxel and carboplatin are frequently used in advanced ovarian cancer following cytoreductive surgery. Threshold models have been used to predict paclitaxel pharmacokinetic-pharmacodynamics, whereas the time ...